Physician
Professional Resource Management of Wiregrass, LLC
Professional Resource Management of Wiregrass, LLC was paid $8.99M by Medicaid between Jan 2018 and Dec 2024, across 111 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 21% of everything it billed.
33Billing provider infoPROFESSIONAL RESOURCE MANAGEMENT OF WIREGRASS, LLC
DOTHAN, AL 36305
DOTHAN, AL 36305
33aNPI1033495221assigned 11/01/2011
33bProvider typePsychiatry Physician
28Total paid$8.99M
24GClaims327,457
24DCodes billed111
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatry Physician providers in Alabama
Rank by total paid#2 of 55
Median peer was paid$43K
This provider vs. median209×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,731 | $803K | |
| 2019 | 37,024 | $952K | |
| 2020 | 45,112 | $1.22M | |
| 2021 | 79,336 | $1.85M | |
| 2022 | 60,872 | $1.84M | |
| 2023 | 41,503 | $1.39M | |
| 2024incomplete | 26,879 | $938K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 21% | 48,909 | 35,726 | $1.87M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 10% | 10,319 | 8,757 | $941K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 9.3% | 4,991 | 4,033 | $834K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 8.3% | 17,195 | 13,767 | $745K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.6% | 10,253 | 7,810 | $681K |
| 86769 | 4.8% | 18,893 | 7,269 | $432K | |
| 99243 | 4.1% | 3,601 | 3,236 | $366K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 3.1% | 7,184 | 4,988 | $282K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.8% | 4,263 | 3,085 | $253K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.3% | 11,820 | 8,763 | $204K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.2% | 5,597 | 4,428 | $194K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.6% | 11,439 | 8,729 | $147K |
99 more codes
| 87581 | 1.6% | 6,604 | $143K | |
| 90791 | Psychiatric diagnostic evaluation | 1.3% | 1,453 | $116K |
| 87486 | 1.2% | 5,122 | $111K | |
| 80061 | Lipid panel | 1.2% | 10,514 | $105K |
| 80053 | Comprehensive metabolic panel | 1.2% | 12,597 | $104K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 11,233 | $91K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 808 | $89K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 6,670 | $82K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,456 | $81K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 6,776 | $80K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,324 | $79K |
| 64636 | <1% | 1,508 | $76K | |
| 84146 | <1% | 3,506 | $73K | |
| 64635 | <1% | 730 | $68K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,748 | $67K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 12,836 | $63K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,978 | $59K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,915 | $48K |
| 93000 | <1% | 3,069 | $43K | |
| 95816 | <1% | 461 | $39K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 430 | $39K |
| 82607 | <1% | 2,471 | $36K | |
| 82947 | <1% | 10,976 | $28K | |
| 84481 | <1% | 3,228 | $27K | |
| 82746 | <1% | 2,109 | $25K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,032 | $24K |
| 81025 | <1% | 9,402 | $22K | |
| 77003 | <1% | 1,035 | $20K | |
| 83735 | <1% | 3,037 | $19K | |
| 84439 | <1% | 3,213 | $15K | |
| 64555 | <1% | 36 | $9K | |
| 64713 | <1% | 43 | $9K | |
| 95886 | <1% | 82 | $8K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 4,273 | $8K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 2,653 | $8K |
| 76881 | <1% | 179 | $8K | |
| 95957 | <1% | 81 | $7K | |
| 90674 | <1% | 437 | $7K | |
| 86328 | <1% | 301 | $7K | |
| 81002 | <1% | 2,945 | $6K | |
| 82172 | <1% | 430 | $5K | |
| 87505 | <1% | 73 | $5K | |
| Q3014 | Telehealth originating site facility fee | <1% | 543 | $4K |
| 93922 | <1% | 115 | $4K | |
| 94060 | <1% | 192 | $4K | |
| 87482 | <1% | 73 | $4K | |
| 95923 | <1% | 107 | $4K | |
| 64479 | <1% | 58 | $4K | |
| 94729 | <1% | 191 | $4K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 343 | $3K |
| 86160 | <1% | 350 | $3K | |
| 83690 | <1% | 518 | $3K | |
| 94727 | <1% | 189 | $3K | |
| 86308 | <1% | 522 | $3K | |
| 64480 | <1% | 62 | $3K | |
| 83615 | <1% | 508 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,047 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 170 | $2K |
| 83540 | <1% | 289 | $2K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 13 | $2K |
| 95921 | <1% | 89 | $2K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 103 | $2K |
| 84466 | <1% | 160 | $2K | |
| 94200 | <1% | 190 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 411 | $1K |
| 0011A | <1% | 38 | $1K | |
| 83695 | <1% | 215 | $1K | |
| 72100 | <1% | 67 | $1K | |
| 86215 | <1% | 164 | $1K | |
| 83874 | <1% | 204 | $1K | |
| 80183 | <1% | 96 | $1K | |
| 86141 | <1% | 219 | $1K | |
| 84153 | <1% | 89 | $1K | |
| 92273 | <1% | 15 | $865.80 | |
| 87109 | <1% | 56 | $840.00 | |
| 90686 | <1% | 55 | $790.22 | |
| 87070 | <1% | 56 | $616.00 | |
| 86063 | <1% | 92 | $469.00 | |
| 86431 | <1% | 159 | $405.00 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 498 | $380.08 |
| 87641 | <1% | 16 | $352.00 | |
| 87500 | <1% | 16 | $352.00 | |
| 83883 | <1% | 28 | $340.00 | |
| 82373 | <1% | 157 | $297.00 | |
| 86140 | <1% | 198 | $280.00 | |
| 82784 | <1% | 28 | $240.00 | |
| 80305 | <1% | 128 | $188.46 | |
| 82232 | <1% | 14 | $180.00 | |
| 82785 | <1% | 14 | $162.20 | |
| 83520 | <1% | 15 | $123.62 | |
| 82787 | <1% | 28 | $100.00 | |
| 99307 | <1% | 24 | $64.65 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 23 | $21.48 |
| 81228 | 0% | 66 | $0.00 | |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | 0% | 63 | $0.00 |
| J3490 | Unclassified drugs | 0% | 2,025 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 29 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 46 | $0.00 |
| 71020 | 0% | 35 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGILLEY, NANCY (AUTHORIZED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Professional Resource Managment of Wiregrass, LLC | Ozark, AL | $748K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.